# D2C7-IT + 2141-V11 Combination Post-resection in rGBM

> **NCT06455605** · PHASE1 · RECRUITING · sponsor: **Darell Bigner** · enrollment: 46 (estimated)

## Conditions studied

- Recurrent Glioblastoma IDH Wildtype

## Interventions

- **DRUG:** D2C7-IT
- **DRUG:** 2141 V11

## Key facts

- **NCT ID:** NCT06455605
- **Lead sponsor:** Darell Bigner
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-17
- **Primary completion:** 2029-01-31
- **Final completion:** 2030-01-31
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06455605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06455605, "D2C7-IT + 2141-V11 Combination Post-resection in rGBM". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06455605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*